在非糖尿病患者中引起IGF-2介导的低血糖症的孤独性膜纤维瘤
Emily Lachmann1, Benjamin Bennett2, Rozana Ramli3
1Internal Medicine, Cambridge University Hospitals, Cambridge, UK.
BMJ case reports
|March 7, 2024
概括
一种罕见的肺瘤在一个非糖尿病患者中引起了复发性低血糖症. 这一案例凸显了除了糖尿病之外,调查低血糖病因的重要性.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 肺部病理学 肺部病理学
背景情况:
- 低血糖,或低血糖,可以有各种原因.
- 非糖尿病低血糖症需要彻底调查以确定潜在的条件.
研究的目的:
- 为了呈现一种罕见瘤的次要低血糖病例.
- 强调非糖尿病低血糖的诊断考虑因素.
- 为了突出单一的肺膜纤维瘤与胰岛素类生长因子2 (IGF-2) 生产之间的关联.
主要方法:
- 一个患有低血糖和跌倒的患者的临床表现.
- 诊断工作包括实验室测试和计算机断层扫描 (CT) 扫描.
- 鉴定一个单独的膜纤维瘤作为致病剂.
主要成果:
- 患者出现了重复的夜间禁食低血糖症.
- 电脑图像扫描显示出一个巨大的肺部质量,被确定为单一的肺部纤维瘤.
- 瘤与胰岛素类生长因子2 (IGF-2) 的产生有关.
结论:
- 孤独性膜纤维瘤是由于IGF-2产生的低血糖症的罕见原因.
- 患有低血糖症的非糖尿病患者需要全面的诊断评估.
- 这一案例强调了在无法解释的低血糖症下考虑副瘤综合征的重要性.
相关概念视频
Hypoglycemia and Glucagon
260
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
260
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Glucose Transporters
22.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.8K
Diabetes: Symptoms, Diagnosis, and Complications
534
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
534
Dipeptidyl Peptidase 4 Inhibitors
186
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
186


